PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.57%
Revenue growth 1.25-1.5x META's 14.89%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
26.90%
Gross profit growth above 1.5x META's 16.27%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
75.67%
EBIT growth above 1.5x META's 34.83%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
75.67%
Operating income growth above 1.5x META's 34.83%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
61.62%
Net income growth 1.25-1.5x META's 51.53%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
62.75%
EPS growth 1.25-1.5x META's 51.10%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
60.78%
Diluted EPS growth 1.25-1.5x META's 50.56%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
-0.34%
Share reduction while META is at 0.50%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.17%
Reduced diluted shares while META is at 0.56%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
21.51%
OCF growth under 50% of META's 153.43%. Michael Burry might suspect questionable revenue recognition or rising costs.
34.82%
FCF growth under 50% of META's 885.39%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
494.35%
10Y revenue/share CAGR under 50% of META's 1811.89%. Michael Burry would suspect a lasting competitive disadvantage.
149.64%
5Y revenue/share CAGR under 50% of META's 369.75%. Michael Burry would suspect a significant competitive gap or product weakness.
69.65%
3Y revenue/share CAGR at 50-75% of META's 112.42%. Martin Whitman would question if the firm lags behind competitor innovations.
452.55%
10Y OCF/share CAGR under 50% of META's 1377.74%. Michael Burry would worry about a persistent underperformance in cash creation.
185.80%
5Y OCF/share CAGR at 50-75% of META's 341.54%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
75.75%
3Y OCF/share CAGR 1.25-1.5x META's 63.88%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
386.77%
Below 50% of META's 2836.32%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
185.40%
Below 50% of META's 767.19%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
70.47%
3Y net income/share CAGR similar to META's 70.44%. Walter Schloss would attribute it to shared growth factors or demand patterns.
361.29%
Equity/share CAGR of 361.29% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
84.95%
Below 50% of META's 179.91%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
38.30%
3Y equity/share CAGR at 50-75% of META's 68.94%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.14%
AR growth well above META's 7.23%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.45%
Inventory growth of 2.45% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
7.45%
Asset growth above 1.5x META's 4.83%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.05%
50-75% of META's 6.07%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
68.98%
Debt growth far above META's 0.80%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.28%
Our R&D shrinks while META invests at 6.75%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
7.72%
SG&A growth well above META's 0.90%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.